With increasing biomarker-driven cancer treatments, TEPMETKO benefits from growing adoption in precision oncology. Competition from other MET inhibitors like TABRECTA (capmatinib) exists, but ...

Who doesn’t love a great action RPG experience? Fortunately, we’ll have more than a few to pick from in 2025. Plenty of games are getting the “remake” treatment, and the Gothic 1 Remake ...

Bristol-Myers Squibb released financial results for Q4 2024. Check out why I am upgrading BMY stock's rating from 'Buy' to 'Strong Buy'.

For example, January’s free action movies didn’t stick around for February. The positive news is that the three great action movies you should stream right now include a trio of classics.

The Chinese writer and director Wang Xiao Long’s “Blasting” isn’t an action film predicated on rapid shootouts or brutal hand-to-hand combat. Rather, homemade bombs assembled by Lan Xin ...

The drug, Opdualag, blocks two checkpoints—LAG-3 and PD-1—both of which are proteins on immune cells. "It targets two targets, so I thought this would be good," Nath explains. But he again ...

The leading Advanced Melanoma Companies such as OncoSec Medical, Immunocore, Sanofi, TILT Biotherapeutics, Novartis Pharmaceuticals, Sumitomo Pharma, BioMed Valley Discoveries, Replimune, ImaginAb, ...

This word has appeared in 31 articles on NYTimes.com in the past year. Can you use it in a sentence? By The Learning Network This word has appeared in 22 articles on NYTimes.com in the past year ...

It is a good idea to leave them unpruned over winter: they provide food and shelter for wildlife and can look attractive even in decay, particularly when sprinkled with frost on cold mornings ...

Bris­tol My­ers Squibb’s LAG-3/PD-1 tar­get­ing im­munother­a­py Op­du­alag failed to boost sur­vival in pa­tients with ad­vanced skin can­cer in a Phase 3 study, mark­ing the lat ...

Upon Opdualag’s approval in 2022 as a first-in-class cancer immunotherapy, Bristol Myers Squibb was anxious to explore its potential in a variety of indications. But so far, the company is ...